Related Experiment Video

Updated: Jun 26, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K

Cardioprotective effects of vaccination in hospitalized patients with COVID-19

Julian Madrid1, Prerana Agarwal2, Katharina Müller-Peltzer2

  • 1Department of Cardiology, Pneumology, Angiology, Acute Geriatrics and Intensive Care, Ortenau Klinikum, Klostenstraße 19, 77933, Lahr/Schwarzwald, Germany. julian.madrid@ortenau-klinikum.de.

Clinical and Experimental Medicine
|May 17, 2024
PubMed

Insights

COVID-19 vaccination significantly reduces acute cardiac events and lowers cardiac biomarkers in hospitalized patients. This highlights the cardioprotective benefits of vaccination against severe COVID-19 outcomes.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Vaccinology

Background:

  • COVID-19 vaccination is established to prevent and mitigate COVID-19 severity.
  • Hospitalized COVID-19 patients face risks of cardiac complications.
  • The cardioprotective effects of COVID-19 vaccination in this population require further investigation.

Purpose of the Study:

  • To investigate the cardioprotective impact of COVID-19 vaccination among hospitalized COVID-19 patients.
  • To assess the association between vaccination status and acute cardiac events.
  • To evaluate the effect of vaccination on cardiac biomarker levels in hospitalized COVID-19 patients.

Main Methods:

  • Retrospective, single-center cohort study.
  • Inclusion of hospitalized COVID-19 patients with confirmed vaccination status (July 2021-February 2022).
  • Assessment of acute cardiac events, cardiac biomarker levels (troponin T), and risk factors (diabetes, pre-existing cardiac disease).

Main Results:

  • Vaccinated patients showed a reduced relative risk for acute cardiac events (RR: 0.33).
  • Vaccinated individuals exhibited diminished troponin T levels (Cohen's d: -0.52).
  • Type 2 diabetes and pre-existing cardiac diseases were significant risk factors for acute cardiac events.

Conclusions:

  • COVID-19 vaccination appears to offer cardioprotective benefits to hospitalized patients.
  • Vaccination may provide both direct and indirect protective effects against cardiac complications in COVID-19.
  • Identifying risk factors like diabetes and cardiac disease is crucial for managing hospitalized COVID-19 patients.

Keywords:
Acute cardiac eventsBiomarkerCOVID-19 diseaseCardiotropismTroponinVaccination

More Related Videos

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

3.2K
Effects of Surgical Masks on Cardiopulmonary Function in Healthy Subjects06:57

Effects of Surgical Masks on Cardiopulmonary Function in Healthy Subjects

Published on: February 12, 2021

3.2K

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
44.4K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.0K
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
323
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
573
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
203